The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.
Kenneth A. Getz
Advertisement
Articles by Kenneth A. Getz
New research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.
Advertisement
Latest Updated Articles
Tracking Trial Cost Drivers: The Impact of Comparator Drugs and Co-TherapiesPublished: May 1st 2013 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
4
Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments
5
